




FIG. 1

2/140

CD8α1	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQP	60
		MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQP	
m1CD8α	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQP	60
CD8α1	61	RGAAASPTFLLYLSQNKPKAAEGLDTRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSN	120
		RGAAASPTFLLYLSQNKPKAAEGLDTRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSN	
m1CD8α	61	RGAAASPTFLLYLSQNKPKAAEGLDTRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSN	120
CD8α1	121	SIMYFSHFVPVFLPAKPTT-TPAPRPPTPAPTIASQPLSL-RPEACRPAAGGAVHTRGLD	178
		SIMYFSHFVPVFLPA P PT T+ + L RPE T+	
m1CD8α	121	SIMYFSHFVPVFLPASVVDLPTTAQPTKKSTLKKRVCRLEPRPE-----TQKGP	169
CD8α1	179	FACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSQDKPSLSARYV	235
		YIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSQDKPSLSARYV	
m1CD8α	170	LCSPYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSQDKPSLSARYV	226

FIG. 2

CD8α2	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQP	60
		MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQP	
m2CD8α	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQP	60
CD8α2	61	RGAAASPTFLLYLSQNKPKAAEGLDTRFSGKRLGDTFVLTLSDFRRENEG [↓] CYFCSALSN	120
		RGAAASPTFLLYLSQNKPKAAEGLDTRFSGKRLGDTFVLTLSDFRRENEG [↓] CYFCSALSN	
m2CD8α	61	RGAAASPTFLLYLSQNKPKAAEGLDTRFSGKRLGDTFVLTLSDFRRENEG [↓] CYFCSALSN	120
CD8α2	121	SIMYFSHFVPVFLPAKPTT-TPAPRPPTPAPTIASQPLSL-RPEACRPAAGGAVHTRGLD	178
		SIMYFSHFVPVFLPA P PT T+ + L RPE T+	
m2CD8α	121	SIMYFSHFVPVFLPASVVDLPTTAQPTKKSTLKKRVCRLEPRPE-----TQKGP	169
CD8α2	179	FACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSQDKPSLSARYV	235
		YIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSQDKPSLSARYV	
m2CD8α	170	LCSPYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSQDKPSLSARYV	226

FIG. 3




FIG. 4

4/140




FIG. 5A




FIG. 5B




FIG. 6

6/140




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B







FIG. 9A

**FIG. 9B**

10/140

**FIG. 9C**

**FIG. 9D**

12/140




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17





FIG. 18




FIG. 19




FIG. 20A




FIG. 20B




FIG. 20C

25/140




FIG. 21A





FIG. 21B

**FIG. 22**

27/140




FIG. 23A




FIG. 23B

28/140




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 26

31/140




FIG. 27A




FIG. 27B




FIG. 28




FIG. 29A




FIG. 29B




FIG. 30A

36/140




FIG. 30B




FIG. 31A




FIG. 31B




FIG. 32A




FIG. 32B




FIG. 33A




FIG. 33B




FIG. 34A




FIG. 34B




FIG. 35A




FIG. 35B




FIG. 36A




FIG. 36B




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44A




FIG. 44B




FIG. 45A

Tumor Growth Index
(Integrated AUC; normalized to tumor_{only} condition)




FIG. 45B




FIG. 46






FIG. 47

**FIG. 48A****FIG. 48B**




FIG. 48C











FIG. 48D

**FIG. 48E****FIG. 48F**

**FIG. 48G**

**FIG. 49A****FIG. 49B**

**FIG. 49C****FIG. 49D**

67/140




FIG. 49E





FIG. 49F

**FIG. 49G**




FIG. 50A






FIG. 50B

70/140

**FIG. 50C****FIG. 50D**




FIG. 50E





FIG. 50F

**FIG. 50G**

Gated on CD4+CD8+




FIG. 51A




FIG. 51B




FIG. 51C

Gated on CD4-CD8+




FIG. 52A




FIG. 52B




FIG. 52C

Gated on CD3+TCR+




FIG. 53A




FIG. 53B




FIG. 53C





FIG. 54



U.S. G

BSG




FIG. 56




FIG. 57




FIG. 58




FIG. 59




FIG. 60




FIG. 61




FIG. 62




FIG. 63A




FIG. 63B

87/140





FIG. 63C


CD4+ selected	CD8ba.TCR	CD8a*.TCR	TCR
Donor #1	0.51	10.6	-
Donor #2	0.43	4.0	-
Donor #3	1.21	60.0	-

FIG. 63D




	#10	TCR
EC50 (ng/ml)	0.246	0.276
%CD3+tet+	42.2	17.1

FIG. 64A



	#10	TCR
EC50 (ng/ml)	0.360	0.591
%CD3+tet+	54.7	24.2

FIG. 64B



	#10	TCR
EC50 (ng/ml)	0.608	1.549
%CD3+tet+	45.5	16.6

FIG. 64C

Summary EC50_PBMC product Un-normalized E:T::1:1






FIG. 64D




	#10	TCR
EC50 (ng/ml)	0.116	0.295

FIG. 65A






	#10	TCR
EC50 (ng/ml)	0.166	0.153

FIG. 65B



	#10	TCR
EC50 (ng/ml)	0.51	-

FIG. 65C






FIG. 69A









FIG. 69B



**FIG. 71A**

**FIG. 71B**

**FIG. 71C**

**FIG. 71D**

TCR Frequency
(Grouped data, n=4; Armored Dextramer Panel)




FIG. 72A

mbIL15+TCR+ DP Frequency
(Grouped data, n=4; Armored Dextramer Panel)




FIG. 72B




FIG. 72C




FIG. 72D




FIG. 73A




FIG. 73B




FIG. 73C

Grouped Product/hs695T
(*n*=4; TCR+ normalized, 2:1 E/T)




FIG. 74A

112/140




FIG. 74B




FIG. 74C




FIG. 75A

115/140




FIG. 75B




FIG. 75C




FIG. 76A




FIG. 76B




FIG. 76C




FIG. 76D




FIG. 77A




FIG. 77B




FIG. 77C





FIG. 77D



D122; TCR




FIG. 78A




FIG. 78B






FIG. 78C

128/140

D122; mbIL15 alt v3

**FIG. 78D**

D122; mblL15 alt v4

**FIG. 78E**




FIG. 78F

Frequency of DP (Dead) (Grouped data, n=4)




FIG. 78G

Frequency of DN (Live)

(Grouped data, n=4)




FIG. 78H




FIG. 79A




FIG. 79B






FIG. 79C




Note: Conditions with exogenous cytokines were terminated after day 17

FIG. 80A



Note: Conditions with exogenous cytokines were terminated after day 17

FIG. 80B



Note: Conditions with exogenous cytokines were terminated after day 17

FIG. 80C

Grouped Product/UACC257
(*n*=4; TCR+ normalized, 1:1 E/T)




FIG. 81A




FIG. 81B